Akebia Therapeutics
AKBA
#8184
Rank
โ‚น31.59 B
Marketcap
โ‚น117.79
Share price
-3.17%
Change (1 day)
-66.01%
Change (1 year)

Revenue for Akebia Therapeutics (AKBA)

Revenue in 2026 (TTM): โ‚น20.75 Billion

According to Akebia Therapeutics's latest financial reports the company's current revenue (TTM ) is โ‚น22.43 Billion. In 2025 the company made a revenue of โ‚น21.20 Billion an increase over the revenue in the year 2024 that were of โ‚น13.74 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Akebia Therapeutics from 2013 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น20.75 B-2.12%
2025 โ‚น21.20 B54.3%
2024 โ‚น13.74 B-15.19%
2023 โ‚น16.20 B-32.94%
2022 โ‚น24.15 B51.98%
2021 โ‚น15.89 B-26.39%
2020 โ‚น21.59 B-9.6%
2019 โ‚น23.88 B64.46%
2018 โ‚น14.52 B27.82%
2017 โ‚น11.36 B10794.79%
2016 โ‚น0.10 B
2015 N/A
2014 N/A
2013 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
โ‚น9.303 T 41,363.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น5.462 T 24,244.68%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
โ‚น3.593 T 15,915.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
โ‚น5.37 B-76.06%๐Ÿ‡บ๐Ÿ‡ธ USA